MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive gain
-$11,765K
(53.30%↑ Y/Y)
Net gain
-$11,295K
(54.93%↑ Y/Y)
Total other
comprehensive gain
-$470K
(-253.38%↓ Y/Y)
Selling, general, and
administrative
$73,954K
(15.76%↑ Y/Y)
Research and development
compensation and...
$11,045K
(14.60%↑ Y/Y)
Research and
development-ARQ234Program
$11,003K
Cost of sales
$9,222K
(57.61%↑ Y/Y)
Other segment
expenses
$5,861K
(-18.43%↓ Y/Y)
Research and
development-Topical Roflumilast...
$3,307K
(128.70%↑ Y/Y)
Research and
development-Other Programs
$95K
Gain before income
taxes
-$11,202K
(54.80%↑ Y/Y)
Provision for income taxes
$93K
(-66.67%↓ Y/Y)
Unrealized loss on
marketable securities
-$351K
(-156.20%↓ Y/Y)
Foreign currency
translation adjustment
-$119K
(-3075.00%↓ Y/Y)
Interest income
$2,275K
Total operating
expenses
$114,487K
(26.68%↑ Y/Y)
Gain from operations
-$9,089K
(62.95%↑ Y/Y)
Interest expense
$4,368K
(46.48%↑ Y/Y)
Total revenues
$105,398K
(60.07%↑ Y/Y)
Other income
(expense), net
-$20K
(-100.73%↓ Y/Y)
Gain from operations
-$9,089K
(62.95%↑ Y/Y)
Total operating
expenses
$114,487K
(26.68%↑ Y/Y)
Selling, general, and
administrative
$74,076K
(15.74%↑ Y/Y)
Research and development
$30,627K
(74.58%↑ Y/Y)
Cost of sales
$9,784K
(10.80%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)